Daily Archives: October 22, 2014

aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research

– Architect of Novel Translational Rare Disease Programs at NIH Adds Depth to Existing Team of Rare Disease Experts

SAN DIEGO and HONG KONG, Oct. 22, 2014 /PRNewswire/ — aTyr Pharma (“aTyr”), an innovative rare disease therapeutics enterprise, announced today that rare disease expert John C. McKew, Ph.D., joined the company as vice president, research. Dr. McKew brings more than two decades of expertise in translational research, including key leadership positions at the National Institutes of Health, Wyeth Research and Genetics Institute, Inc. (prior to its acquisition by Wyeth). Dr. McKew will lead aTyr’s efforts to expand and translate its novel Physiocrine biology into meaningful therapeutics to treat rare, grave immune-driven disorders.

“John’s team at NIH worked collaboratively with biotech and academic scientists on more than thirty rare disease programs, forging new paths to bring promising preclinical therapeutic ideas into the clinical research setting. His experience across diverse therapeutic areas fits perfectly with our mission to tap Physiocrine biology as a new source of meaningful medicines with the potential to treat a broad spectrum of rare diseases,” said John Mendlein, Ph.D., CEO and executive chairman of aTyr Pharma.  “Our goal is to assemble a world-class team of scientists, physicians, and business experts with unparalleled expertise in rare diseases, to shepherd our promising drugs from product concept through the clinic and ultimately to patients.  We are thrilled to welcome John to aTyr.”

“Physiocrines represent a new area of biology with vast potential to address a myriad of rare diseases. I am excited to be a part of this groundbreaking therapeutic opportunity and look forward to mining aTyr’s biology to identify drug candidates with the potential to benefit patients,” said Dr. McKew. “The existing team is deeply committed to creative and innovative approaches to drug discovery, and I look forward to working alongside these exceptional scientists, physicians and commercial leaders, both in San Diego as well as at Pangu, aTyr’s subsidiary in Hong Kong.”

Dr. McKew most recently served as the acting scientific director of the Division of Preclinical Innovation at the National Center for Advancing Translational Sciences (NCATS) within the National Institutes of Health. His responsibilities included developing both the Therapeutics for Rare and Neglected Disease (TRND) and the Bridging Interventional Development Gaps (BrIDGs) programs. Both programs focus on novel public/private partnerships to advance drug discovery projects through preclinical development into early clinical development. Before joining the NIH, Dr. McKew held a director level position at Wyeth Research in Cambridge, Massachusetts. At Wyeth Research he led a variety of research initiatives including a hit-to-lead chemistry group which supported cardiovascular, musculoskeletal and metabolic disease therapeutic areas. Prior to Wyeth Research, he was employed by Genetics Institute, Inc., where he worked on translating novel inflammation targets into clinical candidates. Dr. McKew is currently an Adjunct Associate Professor at the Boston University School of Medicine. He graduated from State University of New York at Stony Brook with B.S. degrees in Chemistry and Biochemistry. He completed his Ph.D. in Organic Chemistry at University of California, Davis and held post-doctoral research positions at the University of Geneva and Firmenich, SA.

About Physiocrines
Among their various homeostatic functions, some Physiocrines act as extracellular signaling molecules to orchestrate immuno-homeostasis in response to stress and other physiological changes. Physiocrines comprise naturally occurring proteins derived from tRNA synthetases that play fundamental roles in the function of human physiology and restoring pathophysiological states to a healthier state. aTyr is currently focused on Physiocrines that act as endogenous modulators of our immune and regenerative systems. Physiocrines offer the opportunity for modulating biological pathways through newly discovered naturally occurring mechanisms, many of which may provide multiple therapeutic advantages, including improved efficacy and reduced side effect profiles compared to many existing therapeutics.

About aTyr Pharma
aTyr Pharma is developing a pipeline of therapeutic products based on Physiocrine biology. To protect these products aTyr built a dominant intellectual property estate comprising over 200 patent applications and patents. aTyr’s key programs are currently focused on rare disorders where the immune system is imbalanced. These diseases are serious, potentially life-threatening rare diseases, for which there are currently no effective, safe, long-term treatments. The privately held biotech was founded by The Scripps Research Institute Professor Paul Schimmel, a leading aminoacyl tRNA synthetase scientist, and is backed by top life sciences investors Alta Partners, Cardinal Partners, Domain Associates and Polaris Partners. For more information, please visit http://www.atyrpharma.com.

Public Health Sector Offers Immense Opportunities for Global Wound Care Market

– Strong relationships with end users and an effective post sales service strategy must be a priority for wound care companies, says Frost & Sullivan

LONDON, Oct. 22, 2014 /PRNewswire/ — The global wound care market is poised for steady growth due to the rapid rise in lifestyle diseases and the related risk of chronic wounds. A burgeoning population, greater awareness among patients, and higher buying power will further push the market. The emergence of private funding and clinics will also add to demand.

New analysis from Frost & Sullivan, Global Wound Care Market Outlook, finds that the market earned revenues of $8.73 billion in 2013 and estimates this to reach $11.13 billion in 2017. The wound care market in this study included the traditional wound dressings, moist wound dressings, antimicrobial dressings, active therapies, and negative pressure wound therapy.

If you are interested in more information on this study, please email to Anna Zanchi, Corporate Communications, at anna.zanchi@frost.com

“Better awareness among physicians and doctors on the benefits of advanced wound care products that enable faster healing than traditional methods is aiding market expansion,” said Frost & Sullivan Healthcare Senior Research Analyst Parthasarathy Raghava. “Long hospital stay times and increased bed occupancy are viewed as a bigger burden for hospitals than investment in advanced wound care treatment.”

Nevertheless, cost concerns remain. Traditional wound closure products are still preferred over certain expensive solutions such as antimicrobial dressings with silver or hydrocolloid dressings. Focus on prevention and the lack of reimbursement also curbs the wound care therapies market.

“The biggest opportunity for wound care manufacturers and suppliers will emerge from the public healthcare sector and hence, they must work closely with the government to determine and forecast demand in this sector,” noted Raghava. “Players must also widen their product portfolio to gain consumers, particularly as public hospitals opt for bulk purchases to contain costs.”

The home care segment will be another key avenue for revenue generation for wound care solution providers in the global space. Enhancing brand loyalty by establishing a robust relationship with end users and an effective post-sales strategy will be the way forward for companies striving to carve a niche for themselves in the global market.

Global Wound Care Market Outlook is part of the Advanced Medical Technologies Growth Partnership Service program. Frost & Sullivan’s related studies include: Russian Wound Care Market, Western and Eastern European Wound Care and Wound Closure Market, China Wound Care Market, and Wound Care and Wound Closure Market in India. All studies included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants.

About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact
Anna Zanchi
Corporate Communications – Europe
P: +39.02.4851 6133
E: anna.zanchi@frost.com
http://www.frost.com

Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China

Collaboration to address needs of biopharmaceutical companies conducting clinical R&D in China

CAMBRIDGE, Mass. and SHANGHAI, October 22, 2014 /PRNewswire/ Foundation Medicine, Inc. (NASDAQ:FMI) and WuXi PharmaTech (Cayman) Inc. (NYSE:WX) today announced a collaboration to offer Foundation Medicine’s comprehensive genomic profiling to biopharmaceutical companies conducting clinical trials in China.

Under the terms of the collaboration, Foundation Medicine will license and enable WuXi to perform the laboratory component of Foundation Medicine’s FoundationOne® assay at the WuXi Genome Center in Shanghai, the first and only CLIA-certified laboratory in China. Foundation Medicine will offer China-based products and services to global biopharmaceutical partners to support their clinical research and development efforts in China. Financial terms of the collaboration are not being disclosed.

China is poised to become the second-largest pharmaceutical market within the next few years,” said Dr. Ge Li, chairman and chief executive officer of WuXi. “WuXi has seen rapidly increasing demand for molecular profiling services from biopharmaceutical companies as they scale up R&D operations and early development activities in the region. We are pleased to partner with Foundation Medicine, the recognized global leader in comprehensive genomic profiling and a trusted partner of our customers, to provide best-in-class genomic testing to support targeted oncology therapeutic development in China.”

“WuXi is the recognized leader in providing high-quality R&D services in China to the biopharmaceutical industry,” said Michael J. Pellini, M.D., president and chief executive officer of Foundation Medicine. “The development and use of targeted therapies and comprehensive diagnostic tests in oncology are expected to grow significantly in China. WuXi’s leadership position in China makes WuXi an ideal partner as Foundation Medicine expands its global reach to support targeted drug development and clinical entry into this rapidly growing market.”

Foundation Medicine is working with more than 20 biopharmaceutical companies to provide comprehensive genomic profiling in more than 100 studies in 2014 alone. Publicly announced research partners include AstraZeneca, Eisai, Johnson & Johnson, Novartis, and Sanofi.

About Foundation Medicine

Foundation Medicine (NASDAQ: FMI) is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient’s unique cancer. The company’s clinical assays, FoundationOne for solid tumors and FoundationOne Heme for hematologic malignancies, sarcomas and pediatric cancers, provide a fully informative genomic profile to identify the molecular alterations in a patient’s cancer and match them with relevant targeted therapies and clinical trials. Foundation Medicine’s molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer. For more information, please visit http://www.FoundationMedicine.com or follow Foundation Medicine on Twitter (@FoundationATCG).

Foundation Medicine® and FoundationOne® are registered trademarks of Foundation Medicine, Inc.

About FoundationOne®

FoundationOne, the company’s first clinical product, is a fully informative genomic profile for solid tumors used by oncologists to identify the molecular alterations in a patient’s tumor and to match those alterations with relevant targeted therapies and clinical trials. Using next-generation sequencing in routine cancer specimens, FoundationOne interrogates all genes somatically altered in human cancers that are validated targets for therapy or unambiguous drivers of oncogenesis based on current knowledge. It reveals all classes of genomic alterations, including base substitutions, insertions, deletions, copy number alterations and select rearrangements. FoundationOne fits easily into the clinical workflow of the ordering physician, and test results are provided in an easy-to-interpret report supported by a comprehensive review of published literature. FoundationOne is a laboratory-developed test performed at Foundation Medicine’s CLIA-certified lab. The test is accredited by CAP, is approved by the New York State Department of Health and has received a CE Mark. Please visit http://www.FoundationOne.com for more information.

About WuXi PharmaTech

WuXi PharmaTech is a leading open-access R&D capability and technology-platform company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech’s services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. WuXi PharmaTech’s operating subsidiaries are known as WuXi AppTec. For more information, please visit http://www.wuxiapptec.com.

About the WuXi Genome Center

The WuXi Genome Center was established in 2011 to provide sequencing solutions to advance personalized medicine. By integrating with WuXi AppTec’s full range of discovery and development services for the biopharmaceutical industry, the WuXi Genome Center provides a complete solution for drug development projects from target discovery and preclinical and clinical development to personalized medicine. The center meets international clinical standards and is the only CLIA-certified clinical genomics lab in China. In addition to offering sequencing services, WuXi’s genomics lab also provides assay development, validation, and testing services.

Cautionary Note Regarding Forward-Looking Statements for Foundation Medicine

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the commencement of a collaboration with WuXi, the performance by WuXi of the laboratory component of the FoundationOne assay in China, the offer of the FoundationOne assay to biopharmaceutical partners to support research and development activities in China and the expected growth of targeted therapies and comprehensive diagnostic tests in oncology in China. All such forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include the risks that WuXi fails or delays to establish the ability to perform the laboratory component of FoundationOne; that regulatory restrictions delay or restrict the delivery of Foundation Medicine’s comprehensive genomic profiling as contemplated by this collaboration; that the market for biopharmaceutical companies to obtain FoundationOne testing for research and development purposes in China may not develop successfully; and the risks described under the caption “Risk Factors” in Foundation Medicine’s Annual Report on Form 10-K for the year ended December 31, 2013, which is on file with the Securities and Exchange Commission, as well as other risks detailed in Foundation Medicine’s subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Foundation Medicine undertakes no duty to update this information unless required by law.

Foundation Medicine

Media Contact:
Dan Budwick, Pure Communications, Inc.
973-271-6085
dan@purecommunicationsinc.com

Investor Contact:
Khaled Habayeb
617-418-2283
ir@foundationmedicine.com

WuXi PharmaTech

Media Contact:
Aaron Shi
Associate Director of Corporate Communications
+86-21-5046-4362
aaron_shi@wuxiapptec.com

Investor Contact:
Ronald Aldridge
Director of Investor Relations
+1-201-585-2048
ron_aldridge@wuxiapptec.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/foundation-medicine-and-wuxi-pharmatech-announce-strategic-collaboration-to-offer-best-in-class-comprehensive-genomic-profiling-in-china-838463979.html

Golden Meditech Brings in Strategic Investor through the Issuance of Convertible Notes

HONG KONG, Oct. 22, 2014 /PRNewswire/ — Golden Meditech Holdings Limited (the “Company” or “Golden Meditech”, 801.HK; 910801.TW), a leading integrated healthcare enterprise in China, announced that it has brought in Gem Power International Limited as a strategic investor through issuing the convertible notes of an aggregate principal amount of US$20 million (equivalent to approximately HK$155 million). Gem Power International Limited is an indirect wholly-owned subsidiary of CCB International (Holdings) Limited (“CCBI”).

The convertible notes carry a 5% interest per annum and the convertible notes holder can convert the convertible notes into ordinary shares of the Company at an initial conversion price of HK$1.40 (subject to adjustments). Upon full conversion of the principal amount of the convertible notes, the total ordinary shares issuable represents approximately 6.05% of the enlarged share capital of the Company.

Mr. KAM Yuen, Chairman and Chief Executive Officer said, “We are pleased to see CCBI shares the same vision as we do with mainland China’s growing healthcare industry. With the demand for high quality healthcare services and medical devices flourishing, Golden Meditech believes bringing in strategic investor will pave the way for the Company to better capture the opportunities amidst mainland China’s ongoing healthcare reform.”

About Golden Meditech Holdings Limited

Golden Meditech Holdings Limited (www.goldenmeditech.com) is China’s leading integrated-healthcare enterprise. Golden Meditech is a first-mover in China, having established dominant positions in medical devices and healthcare services markets, including cord blood stem cells storage and hospital management, thanks to its strengths in innovation and market expertise and the ability to capture emerging market opportunities. Going forward, the Group will continue to pursue a leading position in China’s healthcare industry both through organic growth and strategic expansion.

 

Frost & Sullivan Recognises Europe’s Top Achievers at Excellence in Best Practices Awards Banquet in Monaco

– More than 20 awards to be presented for exemplary best practices

LONDON, Oct. 22, 2014 /PRNewswire/ — Frost & Sullivan will host its Excellence in Best Practices Awards Banquet at the Monte-Carlo Bay Hotel & Resort in Monaco on 30th October, 2014. The much anticipated, two-part event celebrates the exceptional performances of companies as well as their strategies, processes and executives.

The 2014 Best Practices Awards Banquet features a veritable who’s who of industry’s premier companies and their leaders. The select recipients are chosen by expert industry analysts on the basis of rigorous performance measurements and comparisons using proprietary methodologies.

Jan E. Kristiansen, Senior Partner and Global Head of Growth Consulting at Frost & Sullivan observes: “Our long-established awards programme recognises companies that have demonstrated a unique approach to doing business in their markets.” We are celebrating the innovation, vision and overall contribution of the following exceptional leaders to business and society. 

During the evening awards ceremony, Olivier Courtade, CEO M2M Solutions, Erik Grab, Vice President Strategic Anticipation, Innovation and Sustainable Development, and Martin Peronnet, CEO Monato Telecom, will be accepting Growth, Innovation & Leadership (GIL) awards honouring the exemplary achievements and best practices these individuals continue to demonstrate within their respective domains.

More than 20 awardees have been drawn from a wide spectrum of sectors spanning IT, healthcare, energy, building technologies, automation, banking, aerospace, chemicals, and materials. Some of the areas of excellence in which best-in-class players will be honoured include product leadership, product innovation, customer service leadership, technology innovation as well as competitive strategy innovation and leadership.

On the night, Frost & Sullivan will award, among others, cross-industry giants such as Siemens and Orange; materials majors, DSM Biomedical and Mibelle Group Biochemistry; energy solution innovators, Asetek and Redavia Solar, and technology trailblazers, Artificial Solutions, Cyan Technology and Humavox.

Given below is the complete list of award recipients:

  • Lamda Guard – 2014 Global Aerospace Product Leadership Award
  • Guaranty Trust Bank – 2014 Nigerian Banking for Small and Medium Enterprises Product Leadership Award
  • Chr. Hansen – 2014 Global Wine Industry New Product Innovation Leadership Award
  • DSM Biomedical – 2014 North American Medical Device Coatings Growth Excellence Leadership Award
  • Mibelle Group Biochemistry – 2014 European Anti-Aging Skin Care New Product Innovation Leadership Award
  • Asetek – 2014 Global Data Center Cooling Solutions New Product Innovation Leadership Award
  • Socomec – 2014 European UPS Company of the Year Award
  • Redavia Solar – 2014 Tanzanian Solar/Diesel Hybrid Power Technology Innovation Leadership Award
  • IDT Biologika – 2014 European Biopharmaceutical Contract Manufacturing Customer Service Leadership Award
  • Orange Healthcare and Weinmann Technologies – 2014 European Homecare Monitoring Competitive Strategy Innovation and Leadership Award
  • Edit Microsystems (Pty) Ldt – 2014 South African eEducation Customer Service Leadership Award
  • Keypasco – 2014 European Secure Authentication New Product Innovation Leadership Award
  • Atlas Copco – 2014 European Service Partnership for Compressors Company of the Year Award
  • Emerson Process Management – 2014 European Industrial Services for Process Automation Company of the Year Award
  • Peroni Pompe – 2014 Global Reciprocating Pumps in Oil and Gas Customer Value Leadership Award
  • AlertMe – 2014 European Connected Home in Internet of Things New Product Innovation Leadership Award
  • ADOCIA – 2014 European Therapeutic Proteins Technology Innovation Leadership Award
  • APATEQ – PWT S.A. – 2014 European Advanced Filtration Technology Innovation Leadership Award
  • Artificial Solutions – 2014 European Natural Language Interaction Platform Enabling Technology Leadership Award
  • Cyan Technology Ltd – 2014 European Smart Metering Technology Innovation Leadership Award
  • Humavox – 2014 Israeli Wireless Charging for Wearable Devices Technology Innovation Leadership Award

The Best Practices Awards Banquet showcases the unparalleled accomplishments of leaders and innovators across industry. Join Frost & Sullivan in applauding these luminaries whose visionary leadership and best practices continues to redefine industry standards.

Event Schedule

Venue:              Monte-Carlo Bay Hotel & Resort, Monaco

18:30 – 19:30:    Registration and Drinks Reception

19:35 – 19:45:   Welcome Speech and Keynote Address

19:45 onwards:  Awards Ceremony and Dinner

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants.

Our “Growth Partnership” supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

  • The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
  • The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organisation prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact Us:     Start the discussion

Join Us:           Join our community

Subscribe:       Newsletter on “the next big thing”

Register:         Gain access to visionary innovation

Contact:
Melanie Parkinson
Promotions Co-Ordinator, Europe
Best Practices, Frost & Sullivan
+44-(0)-207-915-7867
melanie.parkinson@frost.com

Tianyin Pharmaceutical Received Notices of Non-Compliance from NYSE MKT

CHENGDU, China, October 22, 2014 /PRNewswire/ — Tianyin Pharmaceutical Inc. (NYSE MKT: TPI, the “Company”), a pharmaceutical company that specializes in the development and sale of patented biopharmaceutical medicine, modernized tra…